Multiple Sclerosis in Pregnancy: A Commentary on Disease Modification and Symptomatic Drug Therapies
Tóm tắt
Multiple sclerosis (MS) frequently affects women of childbearing age, and an increasing number of disease-modifying therapies are available. However, a consequence of this is that women and clinicians face complex shared decisions surrounding disease-modifying therapy use in pregnancy and postpartum. It has been suggested that there are both knowledge and communication gaps that need to be addressed in order to improve outcomes for women with MS desiring a pregnancy. Existing pregnancy studies are subject to limitations including selection bias and missing data; however, when these are combined with clinical expertise, consensus guidelines can be developed and used as a framework to support this complex decision-making process. This commentary paper aims to provide a practical and evidence-based overview of the safety of disease-modifying therapies and symptomatic drug therapies during pregnancy and breastfeeding, along with highlighting where insufficient data exist to guide practice. Multiple sclerosis is more common in women than men, and many women with multiple sclerosis have not completed their families when they are diagnosed. This means that they face complicated decisions around using disease-modifying therapies, many of which have limited evidence for use in pregnancy. Conversations between clinicians and women with multiple sclerosis around pregnancy do not always address all of the issues that women face, partly because not all of the needed information is available. Consensus guidelines have recently been developed, and both experience and opinion have been used to inform these. This paper provides a practical overview of the use of treatments for MS and its symptoms.
Tài liệu tham khảo
citation_journal_title=Ther Adv Neurol Disord; citation_title=Sex and gender issues in multiple sclerosis; citation_author=HF Harbo, R Gold, M Tintoré; citation_volume=6; citation_publication_date=2013; citation_pages=237-248; citation_doi=10.1177/1756285613488434; citation_id=CR1
citation_journal_title=Mult Scler Relat Disord; citation_title=Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: differences between MS specialists and non-MS specialists; citation_author=G Saposnik; citation_volume=57; citation_publication_date=2022; citation_doi=10.1016/j.msard.2021.103389; citation_id=CR2
citation_journal_title=Mult Scler Relat Disord; citation_title=“I’m walking into the unknown”: Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment; citation_author=G Carey; citation_volume=58; citation_publication_date=2022; citation_doi=10.1016/j.msard.2021.103464; citation_id=CR3
citation_journal_title=Mult Scler; citation_title=ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis; citation_author=X Montalban; citation_volume=24; citation_publication_date=2018; citation_pages=96-120; citation_doi=10.1177/1352458517751049; citation_id=CR4
citation_journal_title=Pract Neurol; citation_title=UK consensus on pregnancy in multiple sclerosis: “Association of British Neurologists” guidelines; citation_author=R Dobson; citation_volume=19; citation_publication_date=2019; citation_pages=106-114; citation_doi=10.1136/practneurol-2018-002060; citation_id=CR5
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339:285–291.
citation_journal_title=Mult Scler; citation_title=Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening; citation_author=E Portaccio; citation_volume=28; citation_publication_date=2022; citation_pages=472-479; citation_doi=10.1177/13524585211023365; citation_id=CR7
citation_journal_title=J Neurol; citation_title=Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry; citation_author=K Hellwig; citation_volume=267; citation_publication_date=2020; citation_pages=1715-1723; citation_doi=10.1007/s00415-020-09762-y; citation_id=CR8
citation_journal_title=Mult Scler; citation_title=Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry; citation_author=S Thiel; citation_volume=22; citation_publication_date=2016; citation_pages=801-809; citation_doi=10.1177/1352458516634872; citation_id=CR9
Tecfidera 120mg and 240mg gastro-resistant hard capsules.
https://www.medicines.org.uk/emc/medicine/28593
. Accessed 28 Sept 2022.
citation_journal_title=Neurol Neuroimmunol Neuroinflamm; citation_title=Interim analysis of pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry; citation_author=K Hellwig; citation_volume=9; citation_publication_date=2022; citation_doi=10.1212/NXI.0000000000001114; citation_id=CR11
https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/278772/kerstin.hellwig.effect.of.fingolimod.on.pregnancy.outcomes.in.patients.with.html?f=listing=0*browseby=8*sortby=1*search=p411
. Accessed 28 Sept 2022.
citation_journal_title=Neurotherapeutics; citation_title=Disease reactivation after fingolimod discontinuation in pregnant multiple sclerosis patients; citation_author=A Bianco; citation_volume=18; citation_publication_date=2021; citation_pages=2598-2607; citation_doi=10.1007/s13311-021-01106-6; citation_id=CR13
citation_journal_title=Mult Scler Relat Disord; citation_title=Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors; citation_author=M Sepúlveda; citation_volume=38; citation_publication_date=2020; citation_doi=10.1016/j.msard.2019.101483; citation_id=CR14
citation_journal_title=Mult Scler Relat Disord; citation_title=Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population; citation_author=JB Andersen, MF Wandall-Holm, M Magyari; citation_volume=59; citation_publication_date=2022; citation_doi=10.1016/j.msard.2022.103529; citation_id=CR15
citation_journal_title=Am J Reprod Immunol; citation_title=Evolution of maternofetal transport of immunoglobulins during human pregnancy; citation_author=A Malek, R Sager, P Kuhn, KH Nicolaides, H Schneider; citation_volume=36; citation_publication_date=1996; citation_pages=248-255; citation_doi=10.1111/j.1600-0897.1996.tb00172.x; citation_id=CR16
citation_journal_title=Neurol Neuroimmunol Neuroinflamm; citation_title=Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder; citation_author=AI Ciplea; citation_volume=7; citation_publication_date=2020; citation_doi=10.1212/NXI.0000000000000723; citation_id=CR17
citation_journal_title=Neurology; citation_title=Pregnancy decision-making in women with multiple sclerosis treated with natalizumab; citation_author=E Portaccio; citation_volume=90; citation_publication_date=2018; citation_pages=e823-e831; citation_doi=10.1212/WNL.0000000000005067; citation_id=CR18
citation_journal_title=JAMA Netw Open; citation_title=Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy; citation_author=K Hellwig; citation_volume=5; citation_publication_date=2022; citation_doi=10.1001/jamanetworkopen.2021.44750; citation_id=CR19
citation_journal_title=J Neurol Neurosurg Psychiatry; citation_title=Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis; citation_author=D Landi; citation_publication_date=2022; citation_doi=10.1136/jnnp-2022-329657; citation_id=CR20
citation_journal_title=Curr Opin Neurol; citation_title=Use of disease-modifying drugs during pregnancy and breastfeeding; citation_author=R Dobson, K Hellwig; citation_volume=34; citation_publication_date=2021; citation_pages=303-311; citation_doi=10.1097/WCO.0000000000000922; citation_id=CR21
citation_journal_title=J Hum Lact; citation_title=Transfer of natalizumab into breast milk in a mother with multiple sclerosis; citation_author=TE Baker, SD Cooper, L Kessler, TW Hale; citation_volume=31; citation_publication_date=2015; citation_pages=233-236; citation_doi=10.1177/0890334414566237; citation_id=CR22
citation_journal_title=Neurol Neuroimmunol Neuroinflamm; citation_title=Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions; citation_author=KM Krysko; citation_volume=7; citation_publication_date=2020; citation_doi=10.1212/NXI.0000000000000637; citation_id=CR23
citation_journal_title=Pract Neurol; citation_title=Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines; citation_author=R Dobson; citation_publication_date=2022; citation_doi=10.1136/pn-2022-003426; citation_id=CR24
TOXBASE—poisons information database for clinical toxicology advice.
https://www.toxbase.org/poisons-index-a-z/s-products/selective-serotonin-re-uptake-inhibitors-ssris-in-pregnancy/
. Accessed 28 Sept 2022.
SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery. Gov.uk. 2021.
https://www.gov.uk/drug-safety-update/ssri-slash-snri-antidepressant-medicines-small-increased-risk-of-postpartum-haemorrhage-when-used-in-the-month-before-delivery
. Accessed 28 Sept 2022.
citation_journal_title=BMJ (Clin Res Ed); citation_title=Carbamazepine in pregnancy; citation_author=I Nulman; citation_volume=341; citation_publication_date=2010; citation_doi=10.1136/bmj.c6582; citation_id=CR27
Pregabalin (Lyrica): findings of safety study on risks during pregnancy. Gov.uk. 2022.
https://www.gov.uk/drug-safety-update/pregabalin-lyrica-findings-of-safety-study-on-risks-during-pregnancy
. Accessed 28 Sept 2022.
citation_journal_title=Reprod Toxicol; citation_title=Pregnancy outcomes after in utero exposure to Baclofen; citation_author=N Bernard; citation_volume=34; citation_publication_date=2012; citation_pages=157; citation_doi=10.1016/j.reprotox.2012.05.046; citation_id=CR29
citation_journal_title=JAMA; citation_title=First-trimester pregnancy exposure to modafinil and risk of congenital malformations; citation_author=P Damkier, A Broe; citation_volume=323; citation_publication_date=2020; citation_pages=374-376; citation_doi=10.1001/jama.2019.20008; citation_id=CR30
Committee on Obstetric Practice. Committee opinion no. 717: Sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol. 2017;130:e150–e152.
citation_journal_title=Hum Reprod Update; citation_title=The clinical use of corticosteroids in pregnancy; citation_author=MW Kemp, JP Newnham, JG Challis, AH Jobe, SJ Stock; citation_volume=22; citation_publication_date=2016; citation_pages=240-259; citation_id=CR32
citation_journal_title=JAMA Pediatr; citation_title=Evaluation of long-term outcomes associated with preterm exposure to antenatal corticosteroids: A systematic review and meta-analysis; citation_author=K Ninan, SK Liyanage, KE Murphy, EV Asztalos, SD McDonald; citation_volume=176; citation_publication_date=2022; citation_doi=10.1001/jamapediatrics.2022.0483; citation_id=CR33
Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9.
citation_journal_title=Am J Obstet Gynecol; citation_title=The effect of chronic steroid therapy on glucose tolerance in pregnancy; citation_author=HJ Landy, NB Isada, J McGinnis, R Ratner, JH Grossman; citation_volume=159; citation_publication_date=1988; citation_pages=612-615; citation_doi=10.1016/S0002-9378(88)80019-X; citation_id=CR35
citation_journal_title=Am J Reprod Immunol; citation_title=Evaluation of glucocorticoid compared with immunoglobulin therapy of severe immune thrombocytopenia during pregnancy: Response rate and complication; citation_author=X Xu, M-Y Liang, S Dou, J-L Wang, X-H Zhang; citation_volume=80; citation_publication_date=2018; citation_doi=10.1111/aji.13000; citation_id=CR36
citation_journal_title=Ther Adv Neurol Disord; citation_title=The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results; citation_author=S Thiel, AI Ciplea, R Gold, K Hellwig; citation_volume=14; citation_publication_date=2021; citation_pages=17562864211054956; citation_doi=10.1177/17562864211054956; citation_id=CR37
citation_journal_title=Mult Scler; citation_title=Pregnancy in women with multiple sclerosis in France from 2010 to 2015: incidence, outcomes, and exposure to disease-modifying therapies; citation_author=H Tillaut; citation_volume=28; citation_publication_date=2022; citation_pages=778-789; citation_doi=10.1177/13524585211035376; citation_id=CR38
citation_journal_title=Neurology; citation_title=Pregnancy rates and outcomes in women with and without MS in the United States; citation_author=MK Houtchens, NC Edwards, G Schneider, K Stern, AL Phillips; citation_volume=91; citation_publication_date=2018; citation_pages=e1559-e1569; citation_doi=10.1212/WNL.0000000000006384; citation_id=CR39
citation_journal_title=Neurology; citation_title=Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS; citation_author=MK Houtchens, NC Edwards, AL Phillips; citation_volume=91; citation_publication_date=2018; citation_pages=e1570-e1578; citation_doi=10.1212/WNL.0000000000006382; citation_id=CR40
Swansea University. UK MS pregnancy register.
https://www.ukmsregister.org/pregnancy
. Accessed 28 Sept 2022.